Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

11297	Companies
251092	Keywords
180040	Articles
136931	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 05/14/2024 at 22:05, 2 years 5 months ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website

Clinical Development Collaborations Protagonist Therapeutics Rusfertide EHA Congress

Accesswire

Published on 11/09/2026 at 14:30, 22 minutes ago

Boron One Applies for New Exploration Licence
Published on 11/09/2026 at 14:15, 37 minutes ago

Jericho Energy Ventures to Participate in Cantor Convergence 4th Annual Crypto and AI Infrastructure Conference
Published on 11/09/2026 at 14:00, 52 minutes ago

Tectonic Metals Adds Mine Development and Alaska Native Partnership Leaders Ahead of 2027 Mineral Resource Estimate and Preliminary Economic Assessment
Published on 11/09/2026 at 13:35, 1 hour 17 minutes ago

Gabriel Provides Corporate Update
Published on 11/09/2026 at 13:30, 1 hour 22 minutes ago

Meta Critical Minerals Accepts Invitation to Join Critical Minerals Consortium at the U.S. Military Academy at West Point

View all ACCESSWIRE

EQS Group

Published on 11/09/2026 at 14:48, 3 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Bodycote plc
Published on 11/09/2026 at 14:48, 3 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 11/09/2026 at 14:47, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Mitie Group plc
Published on 11/09/2026 at 14:44, 7 minutes ago

EQS-Adhoc: Ernst Russ AG: Upward revision of the forecast for the financial year 2026
Published on 11/09/2026 at 14:44, 7 minutes ago

Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Add

Les Echos

Published on 11/09/2026 at 14:31, 20 minutes ago

261109 BENETEAU Transactions sur actions propres
Published on 11/09/2026 at 10:32, 4 hours 20 minutes ago

Disclosure of shares outstanding and voting rights - 09.11.2026
Published on 11/09/2026 at 10:32, 4 hours 20 minutes ago

Déclaration nombre d'actions et droits de vote - 09.11.2026
Published on 11/09/2026 at 07:00, 7 hours 52 minutes ago

bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 7 hours 52 minutes ago

BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA

View all LES ECHOS COMFI WIRE